Thrixen develops a diagnostic technology platform utilizing proprietary engineered protein binders and a unique assay format to enable rapid biomarker detection at the point of care. This approach makes essential diagnostics accessible and affordable, addressing the need for timely medical testing in various healthcare settings.
Funding
$7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current biomarker detection methods often require specialized laboratory equipment and trained personnel, limiting accessibility and delaying time-to-results, especially in point-of-care settings. This can hinder timely diagnosis and treatment decisions.
Solution
Thrixen is developing a diagnostic technology platform that enables rapid biomarker detection at the point of care. The platform utilizes proprietary engineered protein binders and a unique assay format to deliver accessible and affordable diagnostic testing. This approach aims to bring essential diagnostics closer to patients, allowing for faster and more informed medical decisions.
Target Audience
The primary target audience includes healthcare providers in point-of-care settings, as well as hospitals and clinics seeking to improve diagnostic accessibility and speed.
Features
- Proprietary engineered protein binders for enhanced biomarker specificity
- Unique assay format designed for rapid results
- Point-of-care testing capabilities, eliminating the need for centralized labs
- Affordable diagnostic testing solutions